Citations

Showing 10 of 108083 citations.

Use of Prophylactic Anticoagulation and the Risk of Hepatic Veno-Occlusive Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Imran, H., Tleyjeh, I.M., Zirakzadeh, A., Rodriguez, Vilmarie , Khan, S.P.

Mayo Clinic

Journal of Investigative Medicine | January 6, 2023 | Volume: 54 | Issue: 2_suppl | Pages: 378-379

10.1177/108155890605402s113 Get It

Subcutaneous Interleukin-4 for Relapsed Non-Hodgkin's Lymphoma: A Phase Ii Trial in the North Central Cancer Treatment Group, Ncctg 91-78-51
Tschetter, Loren K., Allred, Jake, Kurtin, Paul J. , Putnam, Wesley D., Rowland, Kendrith M. , Wiesenfeld, Martin, Soori, Gamini S. , Tenglin, Richard C., Bernath, Albert M., Witzig, T. E., Kurtz, David M. , Geyer, S.M.

Mayo Clinic

Journal of Investigative Medicine | January 6, 2023 | Volume: 55 | Issue: 2 | Pages: 362-362

10.1177/108155890705500281 Get It

Number of Patient Encounters in Emergency Medicine Residency Does Not Correlate with In-Training Exam Domain Scores
Kern, Michael B., Hekman, Dann, Schnapp, Benjamin , Kern, Michael W, Jewell, Corlin , Hekman, Dann

Mayo Clinic

Western Journal of Emergency Medicine | January 6, 2023 | Volume: 24 | Issue: 1 | Pages: 115-119

10.5811/westjem.2022.11.57997 | PMID 36602486 Get It

Introduction: Emergency medicine (EM) residents take the American Board of Emergency Medicine (ABEM) In-Training Examination (ITE) every year. This examination is based on the ABEM Model of Clinical Practice (Model). The purpose of this study was to determine whether a relationship exists between the number of patient encounters a resident sees within a specific clinical domain and their ITE performance on questions that are related to that domain. Methods: Chief complaint data for each patient encounter was taken from the electronic health record for EM residents graduating in three consecutive years between 2016-2021. We excluded patient encounters without an assigned resident or a listed chief complaint. Chief complaints were then categorized into one of 20 domains based on the 2016 Model. We calculated correlations between the total number of encounters seen by a resident for all clinical years and their ITE performance for the corresponding clinical domain from their third year of training. Results: Available for analysis were a total of 232,625 patient encounters and 69 eligible residents who treated the patients. We found no statistically significant correlations following Bonferroni correction for multiple analyses. Conclusion: There was no correlation between the number of patient encounters a resident has within a clinical domain and their ITE performance on questions corresponding to that domain. This suggests the need for separate but parallel educational missions to achieve success in both the clinical environment and standardized testing.
Mastery, models, messengers, and mixed emotions: Examining the development of engineering self‐efficacy by gender
Chen, Xiao‐Yin , Usher, Ellen L. , Roeder, Madelyn , Johnson, Alecia R. , Kennedy, Marian , Mamaril, Natasha A. , Usher, Ellen L , Roeder, Madelyn L.

Mayo Clinic

Journal of Engineering Education | January 6, 2023 | Volume: 112 | Issue: 1 | Pages: 64-89

10.1002/jee.20494 Get It

Abstract Background Engineering self‐efficacy, or the belief in one's own capabilities to complete engineering tasks, has been shown to predict greater motivation, academic performance, and retention of engineering students. Investigating the types of experiences that influence engineering students' self‐efficacy can reveal ways to support students in their undergraduate engineering programs. Purpose/Hypothesis(es) The purpose of this study was to qualitatively examine how undergraduate engineering students describe the sources of their engineering self‐efficacy and whether patterns in students' responses differed by gender. Design/Method Participants ( N = 654) were undergraduate engineering students attending two public, land‐grant universities in the U.S. Open‐ended survey questions were used to identify the events, social experiences, and emotions that students described as relevant to their engineering self‐efficacy. Chi‐square analyses were used to investigate whether response patterns varied by gender. Results Students described enactive performances as their most salient source of self‐efficacy, but interesting insights also emerged about how engineering students draw from social and emotional experiences when developing their self‐efficacy. Women more often referred to social sources of self‐efficacy and reported fewer positive emotions than did men. Conclusion Findings suggest ways that educators can provide more targeted opportunities for students to develop their self‐efficacy in engineering.
From Alpha to Zeta: A Systematic Review of Zeta Waves
Freund, Brin , Brigham, Tara , Salman, Saif , Kaplan, Peter W. , Tatum, William O. , Freund, Brin E, Brigham, T J , Kaplan, Peter W

Mayo Clinic

Journal of Clinical Neurophysiology | January 6, 2023 | Volume: 40 | Issue: 1 | Pages: 2-8

10.1097/wnp.0000000000000972 | PMID 36604788 Get It

Purpose: Electroencephalogram is used for prognostication and diagnosis in critically ill patients and is vital in developing clinical management algorithms. Unique waveforms on EEG may distinguish neurological disorders and define a potential for seizures. To better characterize zeta waves, we sought to define their electroclinical spectrum. Methods: We performed a systematic review using MEDLINE, Embase, Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Review [through Ovid], Scopus, Science Citation Index Expanded and Emerging Sources Citation Index [through the Web of Science], and Epistemonikos. Grey literature resources were searched. Results: Five hundred thirty-seven articles were identified. After excluding duplicates and reviewing titles, abstracts, and bodies and bibliographies of articles, four studies reported 64 cases describing data from patients with zeta waves, with a prevalence of 3 to 4%. Various and often incomplete clinical, neuroimaging, and EEG data were available. 57 patients (89.1%) had a focal cerebral lesion concordant with the location of zeta waves on EEG. 26 patients (40.6%) had clinical seizures, all but one being focal onset. Thirteen patients (20%) had epileptiform activity on EEG. Typically, zeta waves were located in the frontal head regions, often with generalized, frontal, predominant, rhythmic delta activity and associated with focal EEG suppression. Conclusions: Zeta waves frequently represent an underlying focal structural lesion. Their presence suggests a heightened risk for seizures. The small number of retrospective cases series in the literature reporting zeta waves might be an underrepresentation. We suggest a need for prospective studies of cEEG in critically ill patients to determine their clinical significance.
Removal of the vicinal disulfide enhances the platelet-capturing function of von Willebrand factor
Tischer, Alexander , Moon‐Tasson, Laurie, Auton, Matthew , Auton, Matthew , Tischer, Alexander

Mayo Clinic

Blood | January 5, 2023 | Volume: 141 | Issue: 12 | Pages: 1469-1473

10.1182/blood.2022018803 | PMID 36603190 Get It

Abstract A redox autoinhibitory mechanism has previously been proposed, in which the reduced state of the vicinal disulfide bond in the von Willebrand factor (VWF) A2 domain allows A2 to bind to A1 and inhibit platelet adhesion to the A1 domain. The VWF A1A2A3 tridomain was expressed with and without the vicinal disulfide in A2 (C1669S/C1670S) via the atomic replacement of sulfur for oxygen to test the relevance of the vicinal disulfide to the physiological platelet function of VWF under shear flow. A comparative study of the shear-dependent platelet translocation dynamics on these tridomain variants reveals that the reduction of the vicinal disulfide moderately increases the platelet-capturing function of A1, an observation counter to the proposed hypothesis. Surface plasmon resonance spectroscopy confirms that C1669S/C1670S slightly increases the affinity of A1A2A3 binding to glycoprotein Ibα (GPIbα). Differential scanning calorimetry and hydrogen-deuterium exchange mass spectrometry demonstrate that reduction of the vicinal disulfide destabilizes the A2 domain, which consequently disrupts interactions between the A1, A2, and A3 domains and enhances the conformational dynamics of A1-domain secondary structures known to regulate the strength of platelet adhesion to VWF. This study clarifies that the reduced state of the A2 vicinal disulfide is not inhibitory but rather slightly activating.
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma
Coleman, Jonathan , Yip, Wesley , Wong, Nathan C. , Sjoberg, Daniel D. , Bochner, Bernard H. , Dalbagni, Guido , Herr, Harry W., Eugene, K. , Donahue, Timothy F. , Kim, Kwanghee , Vargas, H. Alberto, Alvim, Ricardo , Ghafoor, Soleen , Benfante, Nicole , Meraney, Anoop, Shichman, Steven J., Kamradt, Jeffrey M., Nair, Suresh , Baccala, Angelo A., Palyca, Paul, Lash, Bradley W. , Rizvi, Muhammad A. , Swanson, Scott K., Muina, Antonio F, Teo, Min Yuen , Bajorin, Dean F. , Coleman, Jonathan A , Cha, Eugene K , Donahue, Timothy F , Pietzak, Eugene J , Hakimi, A Ari , Al-Ahmadie, Hikmat A , Alvim, Ricardo G , Nair, Suresh , Apolo, Andrea B , Iyer, Gopa , Rosenberg, Jonathan E , Teo, Min Y , Bajorin, Dean , Donat, S. Machele

Mayo Clinic

Journal of Clinical Oncology | January 5, 2023 | Volume: 41 | Issue: 8 | Pages: 1618-1625

10.1200/jco.22.00763 | PMID 36603175 Get It

PURPOSE Neoadjuvant chemotherapy (NAC) has proven survival benefits for patients with invasive urothelial carcinoma of the bladder, yet its role for upper tract urothelial carcinoma (UTUC) remains undefined. We conducted a multicenter, single-arm, phase II trial of NAC with gemcitabine and split-dose cisplatin (GC) for patients with high-risk UTUC before extirpative surgery to evaluate response, survival, and tolerability. METHODS Eligible patients with defined criteria for high-risk localized UTUC received four cycles of split-dose GC before surgical resection and lymph node dissection. The primary study end point was rate of pathologic response (defined as < ypT2N0). Secondary end points included progression-free survival (PFS), overall survival (OS), and safety and tolerability. RESULTS Among 57 patients evaluated, 36 (63%) demonstrated pathologic response (95% CI, 49 to 76). A complete pathologic response (ypT0N0) was noted in 11 patients (19%). Fifty-one patients (89%) tolerated at least three complete cycles of split-dose GC, 27 patients (47%) tolerated four complete cycles, and all patients proceeded to surgery. With a median follow up of 3.1 years, 2- and 5-year PFS rates were 89% (95% CI, 81 to 98) and 72% (95% CI, 59 to 87), while 2- and 5-year OS rates were 93% (95% CI, 86 to 100) and 79% (95% CI, 67 to 94), respectively. Pathologic complete and partial responses were associated with improved PFS and OS compared with nonresponders (≥ ypT2N any; 2-year PFS 100% and 95% v 76%, P < .001; 2-year OS 100% and 100% v 80%, P < .001). CONCLUSION NAC with split-dose GC for high-risk UTUC is a well-tolerated, effective therapy demonstrating evidence of pathologic response that is associated with favorable survival outcomes. Given that these survival outcomes are superior to historical series, these data support the use of NAC as a standard of care for high-risk UTUC, and split-dose GC is a viable option for NAC.
Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline
Vikas, Praveen , Messersmith, Hans , Compton, Carolyn C. , Sholl, Lynette M. , Broaddus, Russell R. , Davis, Anjee, Garje, Rohan , Konstantinopoulos, Panagiotis A. , Leiser, Aliza, Norquist, Barbara M. , Overman, Michael J. , Sohal, Davendra , Turkington, Richard , Johnson, Tyler , Compton, Carolyn, Sholl, Lynette , Garje, Rohan , Konstantinopoulos, Panagiotis A , Norquist, Barbara , Overman, Michael J , Sohal, Davendra , Turkington, Richard C , Messersmith, Hans , Estevez-Diz, Maria Del Pilar , Mills, Anne M.

Mayo Clinic

Journal of Clinical Oncology | January 5, 2023 | Volume: 41 | Issue: 10 | Pages: 1943-1948

10.1200/jco.22.02462 | PMID 36603179 Get It

PURPOSE The College of American Pathologists (CAP) has developed a guideline on testing for mismatch repair (MMR) and microsatellite instability (MSI) for patients considered for immune checkpoint inhibitor therapy. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS The CAP guideline was reviewed for developmental rigor by methodologists. An ASCO Endorsement Panel subsequently reviewed the content and the recommendations. RESULTS The ASCO Endorsement Panel determined that the recommendations from the CAP guideline, published on August 3, 2022, are clear, thorough, and based on the most relevant scientific evidence. ASCO endorses Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. RECOMMENDATIONS Within the guideline, MMR immunohistochemistry (IHC), MSI polymerase chain reaction, and MSI next-generation sequencing are all recommended testing options for colorectal cancer, MMR-IHC and MSI-polymerase chain reaction for gastroesophageal and small bowel cancer, and only MMR-IHC for endometrial cancer. No recommendation in favor of any testing method over another could be made for any other cancer. Tumor mutational burden was not recommended as a surrogate for DNA MMR deficiency. If MMR deficiency consistent with Lynch syndrome is detected, it should be communicated to the treating physician. Additional information is available at www.asco.org/molecular-testing-and-biomarkers-guidelines .
Invited Commentary: Making Headway in Care Delivery for Transgender Patients in Radiology
Stowell, Justin T.

Mayo Clinic

RadioGraphics | January 5, 2023 | Volume: 43 | Issue: 2 | Pages: No page available

10.1148/rg.220194 | PMID 36602926 Get It

Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival
Ellingson, Benjamin M. , Wen, Patrick Y. , Chang, Susan M. , Bent, Martin J. van den , Vogelbaum, Michael A. , Li, Shanpeng , Wick, Wolfgang , Lassman, Andrew B. , Galanis, Evanthia , Wick, Wolfgang , Lassman, Andrew B , Weller, Michael , Galanis, Evanthia , van den Bent, Martin J , Ellingson, Benjamin M , Wen, Patrick Yung , Li, Gang , Kim, Jiyoon , Youssef, Gilbert , Gilbert, Mark R. , Groot, John de , Cloughesy, Timothy F.

Mayo Clinic

Neuro-Oncology | January 5, 2023 | Volume: 25 | Issue: 6 | Pages: 1017-1028

10.1093/neuonc/noad002 | PMID 36617262 Get It

Abstract Durable objective response rate (ORR) remains a meaningful endpoint in recurrent cancer; however, the target ORR for single-arm recurrent glioblastoma trials has not been based on historic information or tied to patient outcomes. The current study reviewed 68 treatment arms comprising 4793 patients in past trials in recurrent glioblastoma in order to judiciously define target ORRs for use in recurrent glioblastoma trials. ORR was estimated at 6.1% [95% CI 4.23; 8.76%] for cytotoxic chemothera + pies (ORR = 7.59% for lomustine, 7.57% for temozolomide, 0.64% for irinotecan, and 5.32% for other agents), 3.37% for biologic agents, 7.97% for (select) immunotherapies, and 26.8% for anti-angiogenic agents. ORRs were significantly correlated with median overall survival (mOS) across chemotherapy (R2= 0.4078, P &lt; .0001), biologics (R2= 0.4003, P = .0003), and immunotherapy trials (R2= 0.8994, P &lt; .0001), but not anti-angiogenic agents (R2= 0, P = .8937). Pooling data from chemotherapy, biologics, and immunotherapy trials, a meta-analysis indicated a strong correlation between ORR and mOS (R2= 0.3900, P &lt; .0001; mOS [weeks] = 1.4xORR + 24.8). Assuming an ineffective cytotoxic (control) therapy has ORR = 7.6%, the average ORR for lomustine and temozolomide trials, a sample size of ≥40 patients with target ORR&gt;25% is needed to demonstrate statistical significance compared to control with a high level of confidence (P &lt; .01) and adequate power (&gt;80%). Given this historic data and potential biases in patient selection, we recommend that well-controlled, single-arm phase II studies in recurrent glioblastoma should have a target ORR &gt;25% (which translates to a median OS of approximately 15 months) and a sample size of ≥40 patients, in order to convincingly demonstrate antitumor activity. Crucially, this response needs to have sufficient durability, which was not addressed in the current study.